We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Intercept Pharmaceuticals Inc | NASDAQ:ICPT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 19.00 | 18.66 | 19.02 | 0 | 01:00:00 |
B. Riley will host a PBC panel with industry leaders and physicians followed by analyst-moderated fireside chats with participating companies. Industry leaders will discuss their perspectives on the adoption and utilization of currently approved first-line and second-line (1L and 2L) PBC therapies, as well as the anticipated evolution of the treatment paradigm over the coming years. The discussions will also focus on the field's latest thinking on the mid-to-late-stage therapeutic pipeline, the state of surrogate endpoints, and appropriate target product profiles (TPPs) focused on driving patient-centric liver disease outcomes and quality of life benefits. Intercept’s fireside chat is scheduled for 1:00 p.m. ET.
Webcast DetailsThe event will be webcast live starting at 11:00 a.m. ET on Wednesday, August 24. Intercept’s fireside chat will begin at 1:00 p.m. ET. The webcast will be available here and on the investor page of Intercept’s website at http://ir.interceptpharma.com.
About InterceptIntercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.
ContactFor more information about Intercept, please contact:Investor inquiries: investors@interceptpharma.comMedia inquiries: media@interceptpharma.com
1 Year Intercept Pharmaceuticals Chart |
1 Month Intercept Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions